OncoMyx Therapeutics

OncoMyx Therapeutics is a small company based in Phoenix, Arizona, with 11 employees. OncoMyx Therapeutics focuses on developing treatments for hematologic and solid tumors. Their primary approach utilizes a unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery method. This myxoma program, developed over two decades of research by Professor Grant McFadden, leverages the virus's ability to be carried systemically by human leukocytes to infect tumor cells. The company's research has demonstrated the effectiveness of myxoma, a pox virus, as an oncolytic agent against various tumors in preclinical cell and animal models. Professor McFadden played a key role in sequencing the myxoma virus genome in 1999, paving the way for the development of dozens of genetically engineered constructs for cancer therapy. For further information, visit OncoMyx Therapeutics' website at oncomyx.com.